Brean Capital’s healthcare analyst Jonathan Aschoff came out with a commentary on Neuralstem, Inc. (NASDAQ:CUR), after the company presented an updated analysis of its last completed NSI-566 Phase 1 and 2 trials in ALS at the ANA meeting in Chicago Monday.

Aschoff wrote, “A total of 24 of the 30 ALS patients participating in the trials were discussed in the presentation, with safety of the maximum tolerated stem cell dosage being the primary endpoint. The escalating doses were generally well tolerated, with the most common AE being post-operative pain. Secondary endpoints included forced vital capacity (FVC), ALS Functional Rating Scalerevised (ALSFRSr), and assessment of grip strength, respiratory functions and muscle strength.”

“We continue to expect Neuralstem to adopt an enriched enrollment and to recruit healthier patients that are more likely to benefit from NSI-566 therapy. Beyond ALS, Neuralstem is evaluating NSI-566 for cSCI and ischemic stroke in Phase 1/2 trials, which represent potential upside to our valuation,” the analyst concluded.

Aschoff rates Neuralstem shares a Buy, with a price target of $8, which implies an upside of 556% from current levels.

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of -7.3% and a 32.8% success rate. Aschoff has a -38.2% average return when recommending CUR, and is ranked #3684 out of 3754 analysts.

Out of the 5 analysts polled by TipRanks, 3 rate Neuralstem stock a Buy, 1 rates the stock a Hold and 1 recommends a Sell. With a return potential of 335%, the stock’s consensus target price stands at $5.31.

CUR Chart